Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

LaNova Medicines Announces the IND Approval of LM-299 by NMPA

  • 2024-07-11

  • Share:

SHANGHAI, July 11th, 2024 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-299, an anti-PD-1/VEGF bispecific antibody, has been approved by China NMPA.